0000939767-20-000002.txt : 20200109 0000939767-20-000002.hdr.sgml : 20200109 20200109202740 ACCESSION NUMBER: 0000939767-20-000002 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200107 FILED AS OF DATE: 20200109 DATE AS OF CHANGE: 20200109 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schwab Gisela CENTRAL INDEX KEY: 0001213140 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30235 FILM NUMBER: 20519273 MAIL ADDRESS: STREET 1: 6701 KAISER DRIVE CITY: FREMONT STATE: CA ZIP: 94555 FORMER NAME: FORMER CONFORMED NAME: SCHWAB GISELA MD DATE OF NAME CHANGE: 20030107 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: EXELIXIS, INC. CENTRAL INDEX KEY: 0000939767 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 043257395 STATE OF INCORPORATION: DE FISCAL YEAR END: 0103 BUSINESS ADDRESS: STREET 1: 1851 HARBOR BAY PARKWAY CITY: ALAMEDA STATE: CA ZIP: 94502 BUSINESS PHONE: 6508377000 MAIL ADDRESS: STREET 1: 1851 HARBOR BAY PARKWAY CITY: ALAMEDA STATE: CA ZIP: 94502 FORMER COMPANY: FORMER CONFORMED NAME: EXELIXIS INC DATE OF NAME CHANGE: 20000207 FORMER COMPANY: FORMER CONFORMED NAME: EXELIXIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20000106 4 1 wf-form4_157861964149710.xml FORM 4 X0306 4 2020-01-07 0 0000939767 EXELIXIS, INC. EXEL 0001213140 Schwab Gisela C/O EXELIXIS, INC. 1851 HARBOR BAY PARKWAY ALAMEDA CA 94502 0 1 0 0 Pres, Prod Dev & Med Aff & CMO Common Stock 2020-01-07 4 M 0 50000 5.51 A 375122 D Common Stock 2020-01-07 4 S 0 50000 17.96 D 325122 D Common Stock 14880 I By 401(k) Option (right to buy) 5.51 2020-01-07 4 M 0 50000 0 D 2014-09-18 2020-09-17 Common Stock 50000.0 90000 D Includes 55,494 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2019. Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.62 to $18.25. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of January 6, 2020. The option, representing the right to purchase a total of 240,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 18, 2017. /s/ Jennifer Drimmer Rokovich, Attorney in Fact 2020-01-09